| TOVX 0.41 59.41% | FCHL 0.225 -37.22% | CTNT 0.0548 -42.50% | CMND 1.14 58.42% | BYND 1.16 41.02% | ENVB 3.65 100.55% | WLDS 1.3 -13.91% | TZA 5 -1.57% | LZMH 0.155 -10.71% | NVDA 202.06 0.19% | PLUG 3.22 15.83% | BITO 10.46 -1.60% | TSLL 13.29 -4.39% | INTC 65.7 -4.09% | ONDS 10.73 7.30% | NOK 10.61 2.91% | SOXS 18.63 -1.27% | BMNG 1.55 -3.13% | HIMS 31.01 7.60% | TQQQ 58.08 -0.87% | TSLA 392.5 -2.03% | NFLX 94.83 -2.55% | AAL 12.24 -4.23% | FRMI 5.4 -17.56% | SLNH 1.4 23.89% | BB 5.5 13.17% | NVD 5.59 -0.53% | QXO 24.22 -3.12% | SOFI 19.5 0.36% | SPDN 9.14 0.11% | IONQ 48.32 4.84% | SOXL 95.94 1.33% | SNAP 6 -0.50% | ATAI 4.9 21.59% | GRAB 4.21 0.00% | SQQQ 56.91 0.92% | POET 8.59 18.32% | SIDU 4.34 -18.88% | USAR 22.58 13.18% | MARA 11.63 0.26% | SPY 708.72 -0.20% | PBM 11.3 48.68% | DRIP 5.16 -1.71% | CMPS 9.46 42.04% | ASTS 81 -5.30% | MRVL 147.84 5.83% | BTG 4.94 -1.20% | SRXH 0.1198 -5.67% | QBTS 21.655 -0.16% | ZSPC 1.54 2,400.00%

Taylor Morrison Home Corporation (NYSE: TMHC) Surpasses Earnings and Revenue Estimates

Taylor Morrison Home Corporation (NYSE:TMHC) is a leading national land developer and homebuilder, known for its strategic management of inventory, pricing, and sales pace across its communities. Operating in the Zacks Building Products - Home Builders industry, TMHC has consistently outperformed revenue estimates over the past four quarters.

On October 22, 2025, TMHC reported earnings per share (EPS) of $2.01, surpassing the estimated $1.93. This achievement highlights the company's ability to exceed Wall Street expectations. Despite a year-over-year decline in EPS from $2.37, TMHC still delivered a positive surprise of 9.33%, as highlighted by Zacks.

TMHC's revenue for the third quarter of 2025 was $2.1 billion, slightly lower than the previous year's $2.12 billion. However, this figure exceeded the Zacks Consensus Estimate of $2.04 billion, resulting in a positive surprise of 2.76%. This performance underscores the company's resilience in challenging market conditions.

The company's financial health is further supported by a price-to-earnings (P/E) ratio of approximately 6.86, indicating a relatively low valuation compared to its earnings. TMHC's price-to-sales ratio of about 0.73 suggests the market values the company at less than its annual sales, while the enterprise value to sales ratio is approximately 0.97.

TMHC maintains a strong current ratio of approximately 9.43, reflecting its robust ability to cover short-term liabilities with short-term assets. The debt-to-equity ratio of about 0.36 shows a moderate level of debt compared to equity, indicating a balanced financial structure.

Published on: October 22, 2025